Thursday, July 18, 2019

Intermolecular Stockholders Approve Merck KGaA Proposed Acquisition of Intermolecular

SAN JOSE, Calif., July 17, 2019 /PRNewswire/ -- Intermolecular, Inc. (IMI) announced today that the stockholders of Intermolecular have approved the previously announced proposed acquisition of all outstanding shares of common stock of Intermolecular by Merck KGaA, Darmstadt, Germany, through its subsidiary EMD Group Holding II, Inc. 
At a special meeting held earlier today, the holders of approximately 72% of Intermolecular's outstanding common stock voted in favor of the proposed merger transaction.

The transaction is expected to close in the second half of 2019, subject to the satisfaction or waiver of customary closing conditions. Upon the completion of the proposed transaction, Intermolecular stockholders will be entitled to receive $1.20 in cash subject to the terms of the definitive merger agreement. Intermolecular's common stock will no longer be publicly traded following the closing and will be delisted from the NASDAQ Global Select Market.

No comments:

Post a Comment